Interventions
Where each approach stands and the latest research in our collection. Every overview links to its background sources and recent updates; detailed AI reviews are available where completed.
40 tracked topics · AI-written overviews, not expert-reviewed · Recent updates cover the last 30 days.
- Blood pressure control
Prescription · 1 collected reports
Treating high blood pressure can prevent serious cardiovascular events. In SPRINT, more intensive treatment reduced cardiovascular events and deaths in the higher-risk adults studied. This is direct human outcome evidence, but the appropriate target depends on the person and the risks of treatment; the trial is not a universal target for everyone. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.
AI review not yet available
Explore research → - GLP-1 agonists
Prescription · 12 collected reports
These medicines have moved beyond weight-loss measurements to important clinical outcomes. Semaglutide has an FDA indication for reducing cardiovascular death, heart attack and stroke in adults with established cardiovascular disease and overweight or obesity. That is a benefit for a defined patient group, not evidence that these medicines extend life in otherwise healthy people. Source ↗ Recently: The latest trial-registry update in our collection is dated Oct 13, 2026: “Evidence-Based Longevity Interventions and Targeted Engagement (E.L.I.T.E.)”. Its implications have not yet been summarized in a source-checked review. Read update ↗
AI review not yet available
Explore research → - Growth hormone
Prescription · 1 collected reports
Replacing a diagnosed hormone deficiency is different from giving growth hormone to counter normal ageing. Endocrine guidance does not establish growth-hormone enhancement as an anti-ageing intervention. Changes in body composition alone are not enough to demonstrate better health or longer life, and treatment effects and harms must be assessed together. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.
AI review not yet available
Explore research → - SGLT2 inhibitors
Prescription · 2 collected reports
SGLT2 inhibitors are medicines with benefits for defined metabolic, heart and kidney conditions. Empagliflozin’s indications include reducing serious kidney and cardiovascular outcomes in adults with chronic kidney disease at risk of progression. Those are clinically meaningful outcomes in selected patients, but they do not establish a general anti-ageing benefit for healthy people. Source ↗ Recently: The latest trial-registry update in our collection is dated Oct 13, 2026: “Evidence-Based Longevity Interventions and Targeted Engagement (E.L.I.T.E.)”. Its implications have not yet been summarized in a source-checked review. Read update ↗
AI review not yet available
Explore research → - Shingles vaccination
Prescription · 0 collected reports
The established purpose of shingles vaccination is preventing shingles and its complications. Research suggesting a relationship with lower or later dementia risk adds an interesting question, but this possible additional benefit is separate from the vaccine’s established purpose. Dementia findings should be judged by their study design and should not be presented as guaranteed protection against cognitive decline. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.
AI review not yet available
Explore research → - Statins
Prescription · 0 collected reports
Statins lower cholesterol and can reduce the risk of cardiovascular disease in appropriately selected adults. Their value depends on existing disease, overall cardiovascular risk and age; evidence for starting treatment in older adults without cardiovascular disease is less certain. They are preventive medicines for particular risks, not a general treatment for ageing. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.
AI review not yet available
Explore research → - Testosterone therapy
Prescription · 0 collected reports
Testosterone therapy is intended for defined medical circumstances, not as a general longevity treatment. In 2025, the FDA revised cardiovascular warnings after the TRAVERSE trial and required warnings about increased blood pressure. This illustrates why evidence must be tied to the treated population: reassuring findings for one outcome do not prove anti-ageing benefit or eliminate other risks. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged.
AI review not yet available
Explore research →
| Intervention | Current state & recent changes | Research & review |
|---|---|---|
| Blood pressure control Prescription | Treating high blood pressure can prevent serious cardiovascular events. In SPRINT, more intensive treatment reduced cardiovascular events and deaths in the higher-risk adults studied. This is direct human outcome evidence, but the appropriate target depends on the person and the risks of treatment; the trial is not a universal target for everyone. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged. Explore research → | 1 collected reports AI review not yet available |
| GLP-1 agonists Prescription | These medicines have moved beyond weight-loss measurements to important clinical outcomes. Semaglutide has an FDA indication for reducing cardiovascular death, heart attack and stroke in adults with established cardiovascular disease and overweight or obesity. That is a benefit for a defined patient group, not evidence that these medicines extend life in otherwise healthy people. Source ↗ Recently: The latest trial-registry update in our collection is dated Oct 13, 2026: “Evidence-Based Longevity Interventions and Targeted Engagement (E.L.I.T.E.)”. Its implications have not yet been summarized in a source-checked review. Read update ↗ Explore research → | 12 collected reports AI review not yet available |
| Growth hormone Prescription | Replacing a diagnosed hormone deficiency is different from giving growth hormone to counter normal ageing. Endocrine guidance does not establish growth-hormone enhancement as an anti-ageing intervention. Changes in body composition alone are not enough to demonstrate better health or longer life, and treatment effects and harms must be assessed together. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged. Explore research → | 1 collected reports AI review not yet available |
| SGLT2 inhibitors Prescription | SGLT2 inhibitors are medicines with benefits for defined metabolic, heart and kidney conditions. Empagliflozin’s indications include reducing serious kidney and cardiovascular outcomes in adults with chronic kidney disease at risk of progression. Those are clinically meaningful outcomes in selected patients, but they do not establish a general anti-ageing benefit for healthy people. Source ↗ Recently: The latest trial-registry update in our collection is dated Oct 13, 2026: “Evidence-Based Longevity Interventions and Targeted Engagement (E.L.I.T.E.)”. Its implications have not yet been summarized in a source-checked review. Read update ↗ Explore research → | 2 collected reports AI review not yet available |
| Shingles vaccination Prescription | The established purpose of shingles vaccination is preventing shingles and its complications. Research suggesting a relationship with lower or later dementia risk adds an interesting question, but this possible additional benefit is separate from the vaccine’s established purpose. Dementia findings should be judged by their study design and should not be presented as guaranteed protection against cognitive decline. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged. Explore research → | 0 collected reports AI review not yet available |
| Statins Prescription | Statins lower cholesterol and can reduce the risk of cardiovascular disease in appropriately selected adults. Their value depends on existing disease, overall cardiovascular risk and age; evidence for starting treatment in older adults without cardiovascular disease is less certain. They are preventive medicines for particular risks, not a general treatment for ageing. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged. Explore research → | 0 collected reports AI review not yet available |
| Testosterone therapy Prescription | Testosterone therapy is intended for defined medical circumstances, not as a general longevity treatment. In 2025, the FDA revised cardiovascular warnings after the TRAVERSE trial and required warnings about increased blood pressure. This illustrates why evidence must be tied to the treated population: reassuring findings for one outcome do not prove anti-ageing benefit or eliminate other risks. Source ↗ Recently: No update dated within the past 30 days is recorded in our collection. This describes our coverage, not a conclusion that the wider research is unchanged. Explore research → | 0 collected reports AI review not yet available |